Financial Data and Key Metrics Changes - The company reported a strong top-line growth of 6% core revenue, with significant contributions from pharma and CAM segments [4][8] - The guidance for revenue was raised by 25%, driven by broad-based growth, particularly in pharma and CDMO [4][6] - Gross margins were impacted by tariffs, leading to a 200 basis point decline year-on-year, with expectations for sequential improvement in the fourth quarter [12][14][17] Business Line Data and Key Metrics Changes - Pharma QAQC grew mid-teens in Europe, driven by consolidation of supply chains and new capabilities [6][30] - The CDMO segment experienced a remarkable 20% growth, with bookings extending into 2026 [8][37] - The CAM segment also saw 10% growth in both chemicals and advanced materials, supported by a strong installed base and new investments [44][45] Market Data and Key Metrics Changes - The A and G segment showed stability with mid- to high single-digit growth in Europe and 20% growth in China, although the U.S. market faced challenges [26][27] - In China, the pharma and biopharma sectors are experiencing high innovation rates, with significant out-licensing activity [49][50] - The overall market for PFAS testing is estimated to be around $500 million, with the company growing 50% year-over-year globally [71][75] Company Strategy and Development Direction - The company is focused on innovation and productivity improvements, particularly in the CDMO and pharma segments, which are expected to drive growth in the coming years [31][84] - There is a strong emphasis on maintaining close relationships with customers and enhancing service offerings, particularly in China [62][63] - The company is disciplined in M&A activities, looking for high-quality targets that align with its strategic goals [80][81] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a gradual improvement in the operating environment, despite geopolitical uncertainties and tariff impacts [19][78] - The company anticipates a strong fourth quarter and is optimistic about mid-single-digit growth for the next year, while remaining cautious due to potential external shocks [78][79] - The management highlighted the importance of the Ignite program in driving cost efficiencies and enhancing value creation [85] Other Important Information - The company has seen a shift in customer decision-making processes, with site managers now approving CapEx budgets, indicating a positive trend in capital spending [34] - The BioVectra acquisition is performing well, with expected synergies contributing positively to growth [41][42] Q&A Session Summary Question: What is the outlook for the fourth quarter and next year? - Management raised the implied fourth quarter organic revenue guidance to $5 million to $6 million, indicating optimism for continued growth [76][78] Question: How is the company addressing tariff impacts? - The company expects tariffs to remain high in the fourth quarter but anticipates a reduction in tariff costs by 2026, which will become a tailwind for the business [14][19] Question: What is the status of the PFAS market? - The PFAS market is expected to recover after a temporary slowdown due to regulatory changes, with long-term growth drivers remaining strong [71][73]

REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. “We are excited to welcome Isaac to our board,” said Omid Farokhzad, Chair and CEO of Seer. “Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record o ...

Core Insights - The article emphasizes the importance of efficiency levels in assessing a company's potential for profitability, suggesting that higher efficiency correlates with better price performance [1] Efficiency Ratios - Receivables Turnover: This ratio measures a company's ability to collect debts and extend credit, with a higher ratio indicating better performance [2] - Asset Utilization: This ratio reflects a company's efficiency in converting assets into sales, with higher values suggesting better efficiency [3] - Inventory Turnover: This ratio indicates how well a company manages its inventory relative to its cost of goods sold, with higher values signaling effective inventory management [4] - Operating Margin: This ratio assesses a company's control over operating expenses, with higher values indicating more efficient expense management [5] Screening Criteria - The screening process included a favorable Zacks Rank (1 Strong Buy) alongside the efficiency ratios, narrowing down over 7,906 stocks to 15 strong candidates [6][9] Top Stocks Identified - The top five stocks identified for their efficiency include: - Tsakos Energy Navigation Limited (TEN) with an average four-quarter earnings surprise of 46.7% [10] - 10x Genomics, Inc. (TXG) also with an average four-quarter earnings surprise of 46.7% [11] - Pan American Silver Corp. (PAAS) with an average four-quarter earnings surprise of 45.2% [12] - Wolverine World Wide, Inc. (WWW) with an average four-quarter earnings surprise of 39.1% [13] - Interface (TILE) with an average four-quarter earnings surprise of 33.5% [14]

Financial Data and Key Metrics Changes - The company reported sales of $771 million, reflecting a 9% increase as reported and an 8% increase in constant currency compared to the previous year [16] - Non-GAAP earnings per share (EPS) were $2.95, up 12% year on year, while GAAP EPS was $2.47 [19] - Gross margin for the quarter was 58.3%, and adjusted operating margin was 29.1%, impacted by regional sales mix and tariff surcharges [20] Business Line Data and Key Metrics Changes - Instruments grew in mid-single digits, led by high single-digit growth in the liquid chromatography (LC) and mass spectrometry (MS) portfolio [7] - Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth [8] - Chemistry benefited from approximately $8 million in sales pull forward related to tariff dynamics, with overall constant currency growth rate at 7% and chemistry up 10% [10] Market Data and Key Metrics Changes - By end market, pharma grew low double digits, industrial grew 6%, and academic and government declined low single digits [9][16] - In the Americas, growth was partially offset by weakness in the TA division, particularly in macro-sensitive polymer and materials testing applications [8] - Asia grew 14%, driven by double-digit growth in China, India, and Japan, while Europe grew 8% [18] Company Strategy and Development Direction - The company is focused on three strategic pillars: commercial execution, revitalizing innovation, and capturing long-term growth in high-growth adjacencies [11] - The pending combination with BD's biosciences and diagnostic solutions business is expected to accelerate entry into high-growth adjacencies and enhance the company's growth trajectory [26] - The company raised its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and adjusted EPS guidance to $12.95 to $13.05 [15][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong momentum of the core business and the positive impact of the upcoming combination with BD [26] - The company anticipates a gradual return to growth for BD's biosciences and diagnostics solutions business, with expected growth rates of 4.5% in 2026 and 5% in 2027 [31] - Management acknowledged ongoing industry headwinds in pharma drug discovery and academic funding but remains optimistic about the overall growth potential [30][97] Other Important Information - The company plans to use free cash flow to pay down $100 million of debt and increase cash reserves in the second half of the year [22] - The company expects to deliver $345 million in adjusted EBITDA synergies from the combination with BD by year five, with $200 million in cost synergies and $290 million in revenue synergies [33][37] Q&A Session Summary Question: Can you provide an update on the replacement cycle in LC and competitive dynamics? - Management noted that the LCMS segment continues to grow high single digits, with strong replacement activity among large pharma customers and increasing growth in the CDMO customer base [55] Question: What is the timeline for bringing new products to market in microbiology? - Management indicated that it would take approximately three to five years to fully realize the opportunities in microbiology, with potential product introductions in two to three years [61] Question: How do you expect the margin to evolve in the fourth quarter? - Management expects progressive improvement in margins as volume leverage kicks in, with specific impacts from geographical mix and tariff remediation costs [80] Question: Can you elaborate on the $8 million sales pull forward? - Management expressed confidence in the $8 million figure based on order patterns and discussions with customers, indicating it may impact both Q3 and Q4 [84] Question: What is the outlook for the drug discovery business? - Management stated that the drug discovery segment remains slow, with no significant changes expected in the replacement cycle for this area [97]

Financial Data and Key Metrics Changes - The company reported adjusted EPS of $0.56 for Q3, up from $0.48 in the prior year, while GAAP EPS was $0.14 compared to $0.31 last year [20] - Q3 revenue reached $316.2 million, reflecting a 6% organic growth year over year and a 4% reported growth [20] - Adjusted gross margin was 71.6%, slightly down from 71.9% last year, while adjusted operating margin improved to 34.9%, up 190 basis points from the prior year [22] Business Line Data and Key Metrics Changes - The Protein Sciences segment achieved reported sales of $227.7 million, with organic revenue growth of 7% [25] - The Diagnostics and Spatial Biology segment reported sales of $89.2 million, with both reported and organic growth at 2% [26] - The GMP reagents business saw trailing twelve-month growth of over 13%, while the cell and gene therapy product line had a trailing twelve-month growth rate of over 30% [12][79] Market Data and Key Metrics Changes - North America experienced low single-digit growth, driven primarily by pharma customers, while Europe saw mid single-digit growth led by academic customers [21] - China faced a mid single-digit decline due to challenging economic conditions, but the rest of Asia increased mid-teens [21] - The academic market in the U.S. was flat, impacted by NIH funding uncertainties, while the diagnostics reagents division showed year-to-date growth in the high single digits [15][21] Company Strategy and Development Direction - The company is focused on balancing investments for future growth while driving operational efficiencies, maintaining industry-leading profitability [5] - The FDA's recent emphasis on reducing animal testing is seen as an opportunity for the company's organoid solutions, which are expected to accelerate growth [11] - The company is actively managing tariff impacts through optimization of its global footprint and supply chain adjustments [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating uncertainties related to NIH funding and tariffs, noting that past experiences suggest severe cuts to NIH funding are unlikely [28][66] - The company anticipates a temporary slowdown in growth momentum to low single digits in Q4 due to macro uncertainties [31] - Management remains optimistic about long-term growth prospects, emphasizing the alignment of their product portfolio with NIH research priorities [9][66] Other Important Information - The company returned $12.6 million in dividends and $100 million through stock buybacks during Q3, with a new share repurchase program authorized for up to $500 million [24] - The balance sheet remains strong with $140.7 million in cash and a total leverage ratio well below one times EBITDA [24] Q&A Session Summary Question: Impact of NIH funding uncertainties on guidance - Management indicated that while NIH funding uncertainties are a concern, they believe the impact on long-term growth will be immaterial, as historical trends show Congress often increases NIH budgets despite proposed cuts [66][68] Question: Clarification on pharma growth rates - Management clarified that pharma experienced double-digit growth in Q3, but they expect a step down in organic growth in Q4 due to tariff impacts and academic market slowdowns [36][38] Question: Local manufacturing footprint in China - Management confirmed that tariffs have not changed their strategy for local manufacturing in China, which is seen as beneficial for minimizing cross-border tariff impacts [51] Question: Expectations for fiscal year 2026 - Management stated that they will provide a soft guide for fiscal year 2026 in three months, anticipating more clarity on headwinds affecting end markets [42][63] Question: Biotech customer spending trends - Management noted that biotech funding is sensitive to capital markets, leading to more frugal spending, which was reflected in flat growth for biotech customers in Q3 [88]